# Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache

> **NCT03974360** · PHASE2 · COMPLETED · sponsor: **Danish Headache Center** · enrollment: 100 (actual)

## Conditions studied

- Post-Traumatic Headache
- Mild Traumatic Brain Injury
- Post-Concussion Syndrome

## Interventions

- **DRUG:** AMG 334

## Key facts

- **NCT ID:** NCT03974360
- **Lead sponsor:** Danish Headache Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-05
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-02-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03974360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03974360, "Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03974360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*